Congressional Medicare advisers suggest making brands pay discounts on drugs in the catastrophic phase of Part D, instead of the coverage gap, to discourage them from setting prices extremely high. MedPAC assessed HHS’ proposal to eliminate rebates or make plans share them at the point of sale in 11 pages of dense comments. The commission said it shares the administration’s concerns that the current rebate system might thwart efforts to lower drug prices, but instead of taking a position on...